Amgen Refuses FDA Request to Withdraw Rare Disease Drug Tavneos Amid Data Integrity Concerns

Amgen查看公司主页 has refused the FDA's request to voluntarily withdraw Tavneos查看药品详情, a treatment for the rare autoimmune disorder ANCA-associated vasculitis (搜索)搜索该疾病, from the U.S. market despite regulatory concerns about clinical trial data integrity and safety risks.

The FDA on January 16 asked Amgen查看公司主页 to remove the drug from the market, citing concerns about how ChemoCentryx (搜索)搜索该词条 re-adjudicated primary endpoint results for nine of the 331 patients enrolled in the drug's pivotal clinical trial. ChemoCentryx, which developed Tavneos查看药品详情, was acquired by Amgen in October 2022 for $3.7 billion. The agency also raised concerns about hepatotoxicity (搜索)搜索该疾病, a known infrequent risk of Tavneos, in assessing the drug's benefit-risk profile.

Amgen Stands Behind Drug's Efficacy

Amgen查看公司主页 informed the FDA on January 28 that it would not pull the drug, expressing confidence in Tavneos查看药品详情 based on clinical data and real-world evidence. "We remain confident that Tavneos is an important and effective medicine based on clinical data, real-world evidence and its favorable benefit risk profile," said Murdo Gordon, executive vice president for global commercial operations, during the company's fourth quarter earnings call.

James Bradner, executive vice president of research and development, acknowledged that the FDA action came as a surprise. "We were surprised by this," Bradner admitted on the call, adding that after review, Amgen查看公司主页 is certain that Tavneos查看药品详情 is effective and has a favorable benefit-risk profile.

Clinical Significance for Rare Disease Patients

ANCA-associated vasculitis (搜索)搜索该疾病 is a rare group of disorders that cause inflammation in the blood vessels, leading to organ damage. Prior to Tavneos查看药品详情' approval, patients underwent chemotherapy and long-term steroid use, which can cause serious complications such as mood disorders and immune suppression, according to Bradner.

The Phase III ADVOCATE study demonstrated that patients could avoid steroids and achieve sustained remission out to 52 weeks when Tavneos查看药品详情 was added to the initial round of chemotherapy. Tavneos was approved by the FDA in October 2021 for treating anti-neutrophil cytoplasmic autoantibody (搜索)搜索该靶点-associated vasculitis.

Financial Impact and Market Outlook

Tavneos查看药品详情 generated $152 million in revenue for the fourth quarter and $459 million for all of 2024, representing approximately 1.2% of Amgen查看公司主页's total revenue. Despite the regulatory challenges, analysts remain optimistic about the drug's commercial potential. Truist Securities expects Tavneos to achieve about $600 million in sales for 2026 and peak at $1.2 billion in 2031.

"We view Tavneos查看药品详情 as a small contributor, non-core to the long-term story," Truist Securities noted, suggesting that analysts were unfazed by the FDA action.

Regulatory Next Steps

The FDA has the authority to force a company to remove a drug from the market, but the first step is typically to request a voluntary recall. If a drugmaker refuses, the agency can seek court orders and injunctions to force the matter.

Amgen查看公司主页 executives remained vague about next steps beyond ongoing discussions with the FDA. "We're in discussions with FDA, and we'll answer questions as we talk with them," Bradner noted during the earnings call.

The company continues to enroll patients in a Phase III trial for children aged 6-18 years with ANCA-associated vasculitis (搜索)搜索该疾病. Additionally, Tavneos查看药品详情 is under review in Europe over concerns about the clinical data used to secure approval, adding another layer of regulatory scrutiny for the drug.